CN116761601A - 依达拉奉口服给药用医药组合物及其给药方法 - Google Patents
依达拉奉口服给药用医药组合物及其给药方法 Download PDFInfo
- Publication number
- CN116761601A CN116761601A CN202180075839.XA CN202180075839A CN116761601A CN 116761601 A CN116761601 A CN 116761601A CN 202180075839 A CN202180075839 A CN 202180075839A CN 116761601 A CN116761601 A CN 116761601A
- Authority
- CN
- China
- Prior art keywords
- administration
- edaravone
- pharmaceutical composition
- hours
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020188514 | 2020-11-12 | ||
| JP2020-188514 | 2020-11-12 | ||
| PCT/JP2021/041673 WO2022102737A1 (ja) | 2020-11-12 | 2021-11-12 | エダラボン経口投与用医薬組成物およびその投与方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116761601A true CN116761601A (zh) | 2023-09-15 |
Family
ID=81602356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180075839.XA Pending CN116761601A (zh) | 2020-11-12 | 2021-11-12 | 依达拉奉口服给药用医药组合物及其给药方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11911366B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245303A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JPWO2022102737A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230098267A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116761601A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124062A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021380319B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198014A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228678A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022102737A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024036261A2 (en) * | 2022-08-10 | 2024-02-15 | Kpr U.S., Llc | Occlusion detection system and method for a flow control apparatus |
| EP4559463A1 (en) * | 2023-11-23 | 2025-05-28 | Ferrer Internacional, S.A. | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
| US20190328712A1 (en) * | 2017-01-17 | 2019-10-31 | Treeway Tw001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| WO2020091036A1 (ja) * | 2018-11-02 | 2020-05-07 | 田辺三菱製薬株式会社 | 経口投与用エダラボン懸濁剤 |
| CN111840218A (zh) * | 2016-03-16 | 2020-10-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| JP7012792B2 (ja) | 2020-08-06 | 2022-01-28 | 株式会社 ディー・エヌ・エー | 動画を配信するためのシステム、方法、及びプログラム |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
-
2021
- 2021-11-12 JP JP2022562195A patent/JPWO2022102737A1/ja active Pending
- 2021-11-12 AR ARP210103147A patent/AR124062A1/es unknown
- 2021-11-12 AU AU2021380319A patent/AU2021380319B2/en active Active
- 2021-11-12 CN CN202180075839.XA patent/CN116761601A/zh active Pending
- 2021-11-12 EP EP21891982.7A patent/EP4245303A4/en active Pending
- 2021-11-12 CA CA3198014A patent/CA3198014A1/en active Pending
- 2021-11-12 TW TW110142253A patent/TW202228678A/zh unknown
- 2021-11-12 KR KR1020237017986A patent/KR20230098267A/ko not_active Ceased
- 2021-11-12 WO PCT/JP2021/041673 patent/WO2022102737A1/ja not_active Ceased
- 2021-11-12 IL IL302533A patent/IL302533A/en unknown
- 2021-12-29 US US17/564,538 patent/US11911366B2/en active Active
-
2023
- 2023-12-28 US US18/398,241 patent/US12478611B2/en active Active
-
2025
- 2025-01-07 JP JP2025002313A patent/JP2025061070A/ja active Pending
- 2025-05-22 AU AU2025203773A patent/AU2025203773A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840218A (zh) * | 2016-03-16 | 2020-10-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
| US20190328712A1 (en) * | 2017-01-17 | 2019-10-31 | Treeway Tw001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| CN110461325A (zh) * | 2017-01-17 | 2019-11-15 | 萃微Tw001公司 | 包括口服或胃部施用依达拉奉的治疗 |
| WO2020091036A1 (ja) * | 2018-11-02 | 2020-05-07 | 田辺三菱製薬株式会社 | 経口投与用エダラボン懸濁剤 |
Non-Patent Citations (3)
| Title |
|---|
| SHIMIZU, H,等: "Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 12, no. 01, 31 January 2023 (2023-01-31), pages 77 - 84 * |
| 崔金凤,等: "LC-UV法测定大鼠血浆中依达拉奉及其药动学研究", 药物分析杂志 ., vol. 32, no. 09, 30 September 2012 (2012-09-30), pages 1634 - 1637 * |
| 王婵娟;亢留玉;李玉萍;邹艳丽;梁孟波;敖英;汪晖;: "依达拉奉对实验性高脂血症小鼠的影响", 中国心血管病研究, no. 08, 10 August 2008 (2008-08-10), pages 67 - 69 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12478611B2 (en) | 2025-11-25 |
| TW202228678A (zh) | 2022-08-01 |
| US20220142982A1 (en) | 2022-05-12 |
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| AU2021380319B2 (en) | 2025-03-20 |
| IL302533A (en) | 2023-07-01 |
| US11911366B2 (en) | 2024-02-27 |
| AU2025203773A1 (en) | 2025-06-12 |
| WO2022102737A1 (ja) | 2022-05-19 |
| KR20230098267A (ko) | 2023-07-03 |
| US20240173297A1 (en) | 2024-05-30 |
| AR124062A1 (es) | 2023-02-08 |
| EP4245303A4 (en) | 2024-10-09 |
| CA3198014A1 (en) | 2022-05-19 |
| EP4245303A1 (en) | 2023-09-20 |
| JP2025061070A (ja) | 2025-04-10 |
| AU2021380319A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2388310T7 (es) | Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas | |
| JP2025061070A (ja) | エダラボン経口投与用医薬組成物およびその投与方法 | |
| WO2003068209A1 (en) | Metformin salts of lipophilic acids | |
| US12569469B2 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| CN103989677A (zh) | 去亚甲基小檗碱在制备降血糖药物中的应用 | |
| SE459899B (sv) | Anvaendning av pyridoxin - - ketoglutarat foer framstaellning av en farmaceutisk komposition foer profylax av hypermjoelksyraemi | |
| CN103919775A (zh) | 9-去甲基小檗碱在制备降血糖药物中的应用 | |
| CN109922801A (zh) | 甲硝唑和巴氯芬的混悬剂和稀释剂 | |
| KR101671008B1 (ko) | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 | |
| EP0401056B2 (en) | Glutamine in the treatment of impaired host defences | |
| JP2010111646A (ja) | 潰瘍性大腸炎治療剤 | |
| JP2019034953A (ja) | 体重増加用化合物の長期使用のための組成物と方法 | |
| EP2668851A1 (en) | Liver function-improving agent | |
| CN110755434A (zh) | 化合物palosuran防治骨骼肌萎缩等疾病的用途 | |
| Morgan et al. | Severe peripheral neuropathy complicating legionnaires' disease | |
| Giner et al. | Effect of intravenous or intragastric nutrients on food intake in rats | |
| US10973886B2 (en) | Use of a pharmaceutical composition containing at least one digestive enzyme in artificial feeding | |
| JP2010265186A (ja) | 貧血予防用組成物 | |
| CN111643501A (zh) | Gensci073或其类似物的用途 | |
| KR20250099117A (ko) | 도파민을 포함하는 약학적 주사용액 | |
| CN121985954A (zh) | 用于减少与体重减轻相关的肌肉减少和/或抑制肌肉减少症的方法和组合物 | |
| JP2001226285A (ja) | 小腸成長促進組成物 | |
| Vanderhoof et al. | DEMONSTRATION OF All ADEQUATE BARRIER TO GASTROESOPHAGEAL REFLUX IN THE NEWBORN AND PRETERM INFANT | |
| Pennington | Enteral Nutrition | |
| UA11567U (en) | Method for correcting metabolic disorders in patients with metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: Japan Address after: Osaka Japan Applicant after: Tanabe Seiyaku Co.,Ltd. Address before: Osaka Japan Applicant before: MITSUBISHI TANABE PHARMA Corp. Country or region before: Japan |